#Germany #Düsseldorf #Ozelle #O-Cyte 1 #AI Hematology

Ozelle to Highlight O-Cyte 1 at MEDICA 2026

Ozelle is gearing up to showcase its innovative product, O-Cyte 1, at the upcoming MEDICA 2026 conference in Düsseldorf, Germany. This advanced hematology analyzer promises to revolutionize the field by integrating artificial intelligence (AI) with traditional complete blood count (CBC) analysis. As laboratories increasingly adopt AI-assisted morphology, there's a pressing need for sophisticated systems that extend beyond mere automated cell classification to incorporating detailed cellular imaging for professional review.

The Evolution of Hematology Analysis

In recent years, the landscape of hematology has been transformed by technological advancements. Laboratories are faced with growing demands for accuracy, efficiency, and scalability, particularly as they manage varying sample loads and the expectation of rapid results. O-Cyte 1 aims to meet these demands by combining high-resolution cellular imaging with differentiating white blood cells into seven subpopulations in a single platform. This innovative approach not only enhances morphological analysis but also allows clinical professionals to visualize and confirm results.

During the MEDICA 2026 event, O-Cyte 1 will exhibit its capabilities, showcasing how it processes up to 60 tests per hour. For higher throughput demands, a cascading configuration of six units can achieve as many as 360 tests per hour. This scalability is essential for labs that handle fluctuating testing volumes and highlights Ozelle's commitment to flexibility in laboratory operations.

Key Features of the O-Cyte 1 Analyzer

The O-Cyte 1 is designed with the end user in mind, ensuring that technicians can easily perform maintenance while focusing on their core work. Its integrated reagents kit and essential components minimize routine maintenance. Moreover, built-in self-verification systems and replaceable modules streamline the identification of faults and maintenance tasks, making it an optimal choice for laboratories seeking reliability and ease of use.

Ozelle also prioritizes the ongoing support needed for diagnostic in vitro (IVD) distributors. Scalable configurations mean laboratories can comfortably adapt to changing testing requirements—ensuring that as a lab grows, so can its capabilities without significant infrastructure overhauls.

Future-Ready Solutions for Laboratories

In conjunction with O-Cyte 1, Ozelle will also present additional products, including EHBT-75 and EHBT-50, which integrate imaging techniques with hematology and biochemical analyses, respectively. These products represent a broader strategy to combine various diagnostic modalities into compact platforms, facilitating efficiency and comprehensive analysis in clinical settings.

Moreover, Ozelle will introduce Open Dx, its AI-driven platform designed to enhance report review workflows and simplify the exchange of results among healthcare professionals. This tool exemplifies how technology can aid in more effective patient care and decision-making.

Visit Ozelle at MEDICA 2026

Attendees at MEDICA are encouraged to visit Ozelle’s booth located at Hall 1, Stand D63, from November 16 to 19, 2026. This is an excellent opportunity for healthcare professionals and lab technicians to see O-Cyte 1 and other innovative products in action and engage in discussions regarding future distribution opportunities.

Founded in Silicon Valley in 2014, Ozelle is committed to advancing hematology and diagnostic systems leveraging AI technology, not only for human healthcare but also for veterinary applications. As the field of hematology evolves, Ozelle stands at the forefront of ensuring that diagnostic capabilities are enhanced through innovation and simplicity.